Dong, Liqun
Ma, Qing
Bennett, Michael
Devarajan, Prasad
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P50 DK096418)
Article History
Received: 1 May 2017
Revised: 22 June 2017
Accepted: 23 June 2017
First Online: 28 July 2017
Compliance with ethical standards
: This single-center case–control study was approved by the Institutional Review Board of Cincinnati Children’s Hospital Medical Center. Written informed consent from the legal guardian, and assent from the patient when appropriate, were obtained prior to enrollment.
: P.D. is a co-inventor on patents (7,776,824 and 7,977,110) related to NGAL as a biomarker of kidney injury, and declares licensing agreements with BioPorto Diagnostics and Abbott Diagnostics. All other authors have no conflicts of interest to report.